Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
Update
With gene expression Without gene expression Mutation & CNV Plot
Summary



PDX model details

PDX ID 27.2A
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
 31
Average PDX Generation Time (days +/- SEM) 53 ± 6
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304; 30049486
Markers 27.2A
AR Y
PSA Y
PSMA Y
NE N
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
27.2A AR -4.026 0.061 GSR MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
27.2A BRAF 0.899 3.730 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
27.2A CDH1 -1.088 0.941 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
27.2A CHD1 -13.394 1.858e-04 Homdel MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
27.2A CHD7 0.865 3.642 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
27.2A EZH2 0.899 3.730 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
27.2A FANCA -1.316 0.803 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
27.2A KMT2C 0.899 3.730 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
27.2A MET 0.899 3.730 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
27.2A MYC 0.865 3.642 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
27.2A RB1 -19.432 2.830e-06 Homdel MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19

Clinical Information

Sample Number 27.2A
Sample Site Inguinal lymph node
Sample source Autopsy
Pathology Tumour Diagnosis Adenocarcinoma
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc) 0.0
Treatment Prior to Specimen Collection ADT, docetaxel, abiraterone

Patient Information

Patient Number 27
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) 42
Consent to share data

Patient Tumour Collection (Current Model)
Tumour sample ID 27.2A
Patient Age (binned in 5 year age groups) 70-74
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
27.2A PCDH11X 187 1.0 Missense variant '2/7 . 22.9 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
27.2A TH 69 0.71 Start lost '1/14 . 21.5 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
27.2A TH 69 0.71 Start lost '1/14 . 21.5 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
27.2A SON 125 0.5 Missense variant '3/12 . 25.4 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
27.2A AR — — GSR — — — — Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500